Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS

Next Previous
Trial Profile

A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Aspirin; Cyclophosphamide; Dexamethasone; Enoxaparin sodium; Granulocyte colony-stimulating factors; Melphalan; Prednisone
  • Indications Deep vein thrombosis; Multiple myeloma; Myocardial infarction; Pulmonary embolism; Stroke; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms MPRvsMEL200

    • Most Recent Events

    • 28 Jun 2023 Planned End Date changed from 1 Jun 2022 to 1 Jun 2025.
    • 17 Jun 2021 Results of meta-analysis of randomized controlled trials (IFM 2009, EMN02/HOVON 95, RV-MM-EMN-441, RV-MM-PI-209 and FORTE), assessing association of HDT-AHCT with PFS in newly diagnosed high-risk myeloma, with overall survival being the secondary objective, presented at the 26th Congress of the European Haematology Association
    • 21 Jun 2020 Results of network meta-analysis (NMA) assessing the efficacy of some different maintenance and continuous regimens in MM treatment presented at the 25th Congress of the European Haematology Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top